Sipuleucel-T

Global Cancer Vaccine Market & Clinical Trials Outlook 2028: HPV Vaccine Sales Fueling Growth With Other Investigational Vaccines in Late Stage Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022
Pharmaceutical, Health, Oncology, Algorithm, Awareness, Cervical cancer, BLA, Human papillomavirus infection, Gardasil, Large-cell lung carcinoma, HPV, Cancer, Pancreatic cancer, BCG, Sipuleucel-T, Prostate cancer, Artificial intelligence, US, US FDA, RNA transfection, Machine learning, Company, Patient, Vaccination, Bacillus, Growth, B cell, Vaccine, Pharmaceutical industry

The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The significant increase in the growth of the market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination.
  • Apart from this, several investigational cancer vaccines have progressed towards late-stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.
  • Cancer Vaccines Trials Insight By Company, Country, and Indication
    To date, both therapeutic, as well as preventive cancer vaccines, have gained entry into the global market.

Global Therapeutic Vaccines Market Trends and Forecasts, 2022-2035: Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Target Disease Indication, RoA - ResearchAndMarkets.com

Retrieved on: 
Monday, June 13, 2022
Health, Pharmaceutical, Type, Research, Tice, Melanoma, Public sector, Method, USD, Partnership, Disease, Organization, Prostate cancer, Degenerative disease, Vaccine, Growth, Patient, Bladder cancer, DNA, Sipuleucel-T, Immune system, Adoption, Hepatology, Antibody, Clinical trial, Industry, Hypertension, Administration, Cancer, Safety, Pharmaceutical industry

The "Global Therapeutic Vaccines Market Distribution by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Target Disease Indication, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Therapeutic Vaccines Market Distribution by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Target Disease Indication, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The "Global Therapeutic Vaccines Market, 2022-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the therapeutic vaccines market.
  • One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with therapeutic vaccines market in the mid to long term.
  • What are the different initiatives undertaken by start-up players for the development of therapeutic vaccines in the recent past?

Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

Retrieved on: 
Thursday, February 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, MCRPC, Cancer, Clinical medicine, Prostate cancer, Glutamate carboxypeptidase II, Survival rate, Treatment of cancer, Sipuleucel-T, Prostvac

The results showed a median overall survival (mOS) of 19.7 months, exceeding all other mOS results for existing prostate cancer treatments in their own registration studies.

Key Points: 
  • The results showed a median overall survival (mOS) of 19.7 months, exceeding all other mOS results for existing prostate cancer treatments in their own registration studies.
  • This supports evidence that a combination of Veyonda (NOX66) and the experimental radiopharmaceutical, 177lutetium-PSMA-617, is a long-awaited leap forward in the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
  • This offers a patient with mCRPC a high chance of the cancer responding to treatment to the extent of obtaining a meaningful survival outcome.
  • Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York.

Real-World Evidence Shows Adding PROVENGE® (sipuleucel-T) to Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival by 14.5 Months

Retrieved on: 
Wednesday, October 14, 2020
Stem cells, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Other Health, Cancer vaccines, Clinical medicine, Medicine, Anatomy, Sipuleucel-T, Prostate cancer, Immunotherapy, Prostate, Dendreon, Neuvenge, PROVENGE® (sipuleucel-T), Dendreon

PROVENGE continues to deliver on its promise of helping men with advanced prostate cancer live longer and should be considered when making treatment decisions in daily clinical practice.

Key Points: 
  • PROVENGE continues to deliver on its promise of helping men with advanced prostate cancer live longer and should be considered when making treatment decisions in daily clinical practice.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.
  • A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.

Study Shows African American Men with Advanced Prostate Cancer Treated with PROVENGE® (sipuleucel-T) Live Longer than Caucasian Men

Retrieved on: 
Thursday, March 12, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Prostate cancer, Cancer, Clinical medicine, Neoplasms, MCRPC, Sipuleucel-T, the PROCEED Registry, Prostate Cancer in African American Men, PROVENGE® (sipuleucel-T), Dendreon

These findings add to the growing body of published clinical evidence that PROVENGE extends life in men with mCRPC and underscore its added effectiveness in African American men, said Bruce A.

Key Points: 
  • These findings add to the growing body of published clinical evidence that PROVENGE extends life in men with mCRPC and underscore its added effectiveness in African American men, said Bruce A.
  • No other prostate cancer treatment has shown this level of added benefit in African American men with mCRPC, so these findings are exciting.
  • More than 30,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010.
  • Median OS in men with a baseline PSA >29.48 ng/mL was 22.7 months for African American men and 17.6 months for Caucasian men.

Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45%

Retrieved on: 
Thursday, February 13, 2020
FDA, MEN, Clinical trials, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Oncology, Cancer vaccines, Prostate cancer, Sipuleucel-T, Thierry Breton, PROVENGE® (sipuleucel-T), Dendreon

Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p

Key Points: 
  • Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p
  • More than 150 variations of mCRPC treatment sequences were identified in the analysis, underscoring the importance of developing a structured approach to managing mCRPC patients.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Dendreon Completes Enrollment of Phase 3 ProVent Clinical Trial Evaluating Sipuleucel-T in Men on Active Surveillance

Retrieved on: 
Wednesday, October 30, 2019
Biotechnology, Pharmaceutical, MEN, General Health, Health, FDA, Consumer, Clinical trials, Health, Medicine, Clinical medicine, Dendreon, Cancer vaccines, Sipuleucel-T, Prostate cancer, Clinical trial, The Immune Response Corporation, Simon J. Hall

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial.

Key Points: 
  • Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial.
  • More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS).
  • The randomized, multicenter Phase 3 ProVent trial is assessing the efficacy of sipuleucel-T in reducing histopathologic disease progression in men on AS.
  • Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease.

Largest Real-World Study of Immunotherapy Shows Men with Advanced Prostate Cancer with Low PSA had a Median Survival of Nearly Four Years after Treatment with PROVENGE® (sipuleucel-T)

Retrieved on: 
Wednesday, September 4, 2019
Biotechnology, Pharmaceutical, Oncology, MEN, Health, Consumer, Cancer vaccines, Clinical medicine, Cancer, Medicine, Prostate cancer, Sipuleucel-T, MCRPC, Immunotherapy, Neuvenge, Dendreon, the PROCEED Registry, PROVENGE® (sipuleucel-T), Dendreon

Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN).

Key Points: 
  • Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN).
  • Median baseline PSA levels at mCRPC diagnosis have declined steadily since the approval of PROVENGE in 2010, said Bruce A.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Dendreon Extends Long-Time Presence in Southern California

Retrieved on: 
Monday, May 13, 2019
Health, Oncology, Pharmaceutical, FDA, Consumer, General Health, MEN, Cancer, Dendreon, Prostate cancer, Cancer vaccines, Clinical medicine, Sipuleucel-T, Medicine

The agreement extends Dendreons ten-year presence in the area through 2030.

Key Points: 
  • The agreement extends Dendreons ten-year presence in the area through 2030.
  • Securing our long-term presence in Seal Beach will provide us continued access to the unique pool of professional and technical talent that is integral to our business, said Jim Caggiano, chief executive officer at Dendreon.
  • After overcoming a number of obstacles in its early days, Dendreon has emerged as a rapidly-growing enterprise following a remarkable turnaround that began in 2015.
  • Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease.

Dendreon to Present Long-Term Survival and HEOR Data at American Urological Association Annual Meeting

Retrieved on: 
Friday, May 3, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, FDA, General Health, RTT, Medicine, Clinical medicine, Cancer, Cancer vaccines, Prostate cancer, Sipuleucel-T, Dendreon, Stroke, Infarction, Cerebrovascular disease, Pulmonary embolism

PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Key Points: 
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.
  • Thromboembolic Events:Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE.
  • Vascular Disorders:Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE.
  • Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease.